HRP20200524T1 - Postupak dijagnoze neurodegenerativnih bolesti - Google Patents

Postupak dijagnoze neurodegenerativnih bolesti Download PDF

Info

Publication number
HRP20200524T1
HRP20200524T1 HRP20200524TT HRP20200524T HRP20200524T1 HR P20200524 T1 HRP20200524 T1 HR P20200524T1 HR P20200524T T HRP20200524T T HR P20200524TT HR P20200524 T HRP20200524 T HR P20200524T HR P20200524 T1 HRP20200524 T1 HR P20200524T1
Authority
HR
Croatia
Prior art keywords
prion protein
shear force
conformation
aggregated
aggregated conformation
Prior art date
Application number
HRP20200524TT
Other languages
English (en)
Inventor
Thorsten Lührs
Original Assignee
Senostic Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senostic Health Gmbh filed Critical Senostic Health Gmbh
Publication of HRP20200524T1 publication Critical patent/HRP20200524T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/02—Devices for withdrawing samples
    • G01N1/04—Devices for withdrawing samples in the solid state, e.g. by cutting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/286—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q involving mechanical work, e.g. chopping, disintegrating, compacting, homogenising
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)

Claims (17)

1. Postupak analize prisutnosti prionskog proteina agregirane konformacije povezanog s bolešću u uzorku sisavca dobivenom biopsijom, obuhvaćajući korake a) dodavanja barem jednog prionskog proteina prirodne konformacije uzorku, b) podvrgavanje mješavine, koja sadrži uzorak i barem jedan prionski protein prirodne konformacije, dobivene u koraku a) barem jednom intenzitetu smične sile koji je kontroliran kako bi imao jednoličan intenzitet s rasponom intenziteta od najviše 20% vrijednosti smične sile za predodređen broj ciklusa u predodređenom vremenu aktivnosti smične sile i predodređenom vremenu mirovanja, c) nakon koraka b), određivanje sadržaja prionskog proteina agregirane konformacije za svaki od intenziteta smične sile, naznačen d) usporedbom sadržaja prionskog proteina agregirane konformacije, određenog u koraku c), s predodređenim podacima o sadržaju prionskog proteina agregirane konformacije, pri čemu je sadržaj određen za prionski protein prirodne konformacije podvrgnut istom intenzitetu smične sile kao i u koraku b), pri čemu su predodređeni podaci o sadržaju prionskog proteina agregirane konformacije određeni s obzirom na prionski protein prirodne konformacije u mješavini s referentnim uzorkom i navedeni podaci su predviđeni u bazi podataka koja, povezano s tim podacima, sadrži dijagnozu neurodegenerativne bolesti pacijenta od kojeg dolaze referentni uzorci.
2. Postupak prema zahtjevu 1, naznačen time da se prije koraka b) mješavina dijeli u alikvote i u koraku b) su barem dva alikvota podvrgnuta različitom intenzitetu smične sile svaki i u koraku c) je sadržaj prionskog proteina agregirane konformacije određen za svaki alikvot i u koraku d) se sadržaj prionskog proteina agregirane konformacije određen u koraku c) za svaki alikvot uspoređuje s podacima predodređenog sadržaja prionskog proteina agregirane konformacije.
3. Postupak prema zahtjevu 1 ili 2, naznačen time da se u koraku b) mješavina podvrgava slijedu od barem dva različita intenziteta smične sile i sadržaj prionskog proteina agregirane konformacije se određuje tijekom ili nakon podvrgavanja mješavine svakom od intenziteta smične sile.
4. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se mješavini dodaje barem jedna luminiscentna boja, koja je specifična za prionski protein agregirane konformacije, prije koraka podvrgavanja mješavine barem dvama intenzitetima smične sile i mjerenje luminiscencije boje.
5. Postupak prema zahtjevu 4, naznačen ozračivanjem mješavine svjetlošću koja ima valnu duljinu za poticanje luminiscencije boje i mjerenjem luminiscencije boje tijekom aktivnosti smične sile iz koraka b) ili tijekom faze mirovanja iz koraka b), bez promjene volumena koji zauzima mješavina u odnosu na generator smične sile, koji proizvodi smičnu silu u koraku b).
6. Postupak prema jednom od prethodnih zahtjeva, naznačen ozračivanjem mješavine svjetlošću koja ima valnu duljinu koja je raspršena od strane prionskog proteina agregirane konformacije i mjerenjem raspršenog svjetla koje isijava iz smjese tijekom koraka b), ili tijekom mirovanja od koraka b), sa ili bez promjene volumena koji zauzima mješavina u odnosu na generator smične sile, koji proizvodi smičnu silu u koraku b).
7. Postupak prema jednom od prethodnih zahtjeva, naznačen time da je u koraku b) brzina formiranja prionskog proteina agregirane konformacije određena iz sadržaja prionskog proteina agregiranog stanja utvrđenog kod barem jednog intenziteta smične sile i predodređeni podaci obuhvaćaju brzinu formiranja kod istog intenziteta smične sile.
8. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se sadržaj prionskog proteina agregirane konformacije određuje kao sadržaj koji nastaje kroz vrijeme i brzina stvaranja prionskog proteina agregirane konformacije je određena nelinearnom regresijskom analizom aproksimacije određenog sadržaja prionskog proteina agregirane konformacije koji nastaje kroz vrijeme za svaki intenzitet smične sile.
9. Postupak prema jednom od prethodnih zahtjeva, naznačen dodavanjem barem jednog prionskog proteina agregirane konformacije barem jednom alikvotu mješavine, koja obuhvaća uzorak i barem jedan prionski protein prirodne konformacije, pri čemu se barem jedan prionski protein agregirane konformacije stvara podvrgavanjem prionskog proteina prirodne konformacije jednoličnoj smičnoj sili upravljanoj do raspona intenziteta od najviše 1% jednog intenziteta smične sile.
10. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se istovremeno tretira barem jedan prionski protein prirodne konformacije bez dodavanja uzorka tjelesne tekućine.
11. Korištenje uređaja u postupku prema jednom od prethodnih zahtjeva, pri čemu uređaj obuhvaća generator smične sile, kojim se upravlja kako bi se postigla smična sila od najviše 10% intenziteta smične sile na svaki element volumena mješavine uzorka biopsije tjelesne tekućine ili tkiva i prionskog proteina prirodne konformacije, koja je smještena u spremniku (8), naznačeno izvorom svjetlosti (17), čiji je svjetlosni tok (19) usmjeren na spremnik (8) i koji obuhvaća optički detektor (14), koji je smješten na putu svjetlosnog toka (11) svjetla koje izlazi iz spremnika (8), pri čemu je optički detektor (14) detektor luminiscencije, detektor raspršivanja svjetlosti ili detektor apsorpcije.
12. Korištenje uređaja prema zahtjevu 11, naznačeno time da je detektor (14) povezan s računalom koje je namješteno da svjetlost (11), koja izlazi iz spremnika (8), određuje kao mjeru za sadržaj prionskog proteina agregirane konformacije, pri čemu računalo ima pristup bazi podataka (baza podataka referentnih informacija), koja sadrži predodređene vrijednosti za sadržaj prionskog proteina agregirane konformacije u odnosu na specifične intenzitete smične sile i u odnosu na dijagnozu neurodegenerativne bolesti, koja se odnosi na referentni uzorak, koji je bio korišten za stvaranje predodređenih vrijednosti.
13. Korištenje uređaja prema jednom od zahtjeva 11 do 12, koji obuhvaća barem dva spremnika (8), koji su svaki smješteni u otvoru kućišta (12), koje sadrži optički detektor (14) i izvor svjetla (17), termostat (T) i odjeljak poklopca (L), koji obuhvaća spremnik za osovinu (9a) koja nosi rotor (9), pri čemu su kućišta (12) međusobno povezana i odjeljci poklopca (L) su međusobno povezani.
14. Korištenje uređaja prema jednom od zahtjeva 11 do 13, kod kojeg generator smične sile obuhvaća rotor (9), koji je smješten odmaknuto od statora (10), naznačeno time da stator sadrži izbočine (10e) koje grade lijevak koji se sužava u ulaz (10) koji leži koaksijalno naspram rotora (9).
15. Korištenje uređaja prema jednom od zahtjeva 11 do 14, kod kojeg generator smične sile sadrži stator (10) koji je izgrađen od odlomka zida spremnika (8), koji je za odlomak opsega rotora (9) u stalnom odmaku paralelno prema rotoru (9).
16. Baza podataka na osnovi računala na nosaču podataka za korištenje u postupku za analizu postojanja prionskog proteina agregirane konformacije u uzorku biopsije sisavca povezanog s bolešću i/ili za analizu uzorka biopsije sisavca na neurodegenerativnu bolest, koja je u odnosu s prionskim proteinom agregirane konformacije, pri čemu baza podataka sadrži medicinsku dijagnozu za specifičnu neurodegenerativnu bolest i/ili podvrstu iste povezanu s predodređenim vrijednostima za količine prionskih proteina agregirane konformacije, pri čemu su vrijednosti odvojeno utvrđene za barem dva različita intenziteta smične sile za svaki prionski protein prirodne konformacije, koji je u postupku u skladu s jednim od zahtjeva 1 do 10 dodan uzorku.
17. Baza podataka na osnovi računala na nosaču podataka prema zahtjevu 16, za korištenje u postupku za analizu postojanja prionskog proteina agregirane konformacije, povezanog s bolešću, u uzorku biopsije sisavca i/ili za analizu uzorka biopsije sisavca na neurodegenerativnu bolest, koja je u odnosu s prionskim proteinom agregirane konformacije, naznačeno time da vrijednosti obuhvaćaju brzinu formiranja prionskog proteina agregirane konformacije za svaki od barem dva različita intenziteta smične sile, brzinu disocijacije prionskog proteina agregirane konformacije i/ili izvornu količinu prionskog proteina agregirane konformacije u uzorku.
HRP20200524TT 2014-07-01 2020-03-30 Postupak dijagnoze neurodegenerativnih bolesti HRP20200524T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14175331 2014-07-01
EP14175677.5A EP2963421A1 (en) 2014-07-01 2014-07-03 Process for diagnosis of neurodegenerative diseases
EP15742188.4A EP3164716B1 (en) 2014-07-01 2015-07-01 Process for diagnosis of neurodegenerative diseases
PCT/EP2015/065044 WO2016001334A1 (en) 2014-07-01 2015-07-01 Process for diagnosis of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
HRP20200524T1 true HRP20200524T1 (hr) 2020-06-26

Family

ID=51059333

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200524TT HRP20200524T1 (hr) 2014-07-01 2020-03-30 Postupak dijagnoze neurodegenerativnih bolesti

Country Status (10)

Country Link
US (2) US10900976B2 (hr)
EP (2) EP2963421A1 (hr)
DK (1) DK3164716T3 (hr)
ES (1) ES2781104T3 (hr)
HR (1) HRP20200524T1 (hr)
HU (1) HUE049438T2 (hr)
PL (1) PL3164716T3 (hr)
PT (1) PT3164716T (hr)
SI (1) SI3164716T1 (hr)
WO (1) WO2016001334A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) * 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
KR20200007945A (ko) 2017-05-16 2020-01-22 암프리온, 인코퍼레이티드 미스폴딩된 타우 단백질의 검출
JP7366415B2 (ja) * 2019-07-05 2023-10-23 国立大学法人千葉大学 ホスファチジン酸センサー
US20210002712A1 (en) * 2019-07-05 2021-01-07 National University Corporation Chiba University Phosphatidic acid sensor
EP4115976A1 (en) 2021-07-05 2023-01-11 SeNostic Health GmbH Reaction vessel
CN113609204B (zh) * 2021-09-30 2021-12-24 深圳前海环融联易信息科技服务有限公司 数据关联特征分析方法、装置、设备及介质
WO2023178049A1 (en) * 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
EP4389272A1 (en) 2022-12-19 2024-06-26 Prosperodes GmbH Reaction vessel with stator insert and rotor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2489427A1 (en) 2011-02-16 2012-08-22 Helmholtz-Zentrum für Infektionsforschung GmbH Device and method for production and analysis of prions
CN104781386B (zh) * 2012-09-12 2018-04-06 基纽拜奥股份有限公司 用于进行试验的集成微流体系统、方法和试剂盒

Also Published As

Publication number Publication date
ES2781104T3 (es) 2020-08-28
EP3164716B1 (en) 2020-01-01
PT3164716T (pt) 2020-04-06
US10900976B2 (en) 2021-01-26
EP2963421A1 (en) 2016-01-06
SI3164716T1 (sl) 2020-07-31
EP3164716A1 (en) 2017-05-10
US20200309794A1 (en) 2020-10-01
PL3164716T3 (pl) 2020-10-05
HUE049438T2 (hu) 2020-09-28
WO2016001334A1 (en) 2016-01-07
DK3164716T3 (da) 2020-04-06
US20170146556A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
HRP20200524T1 (hr) Postupak dijagnoze neurodegenerativnih bolesti
Al-Juboori et al. Light scattering properties vary across different regions of the adult mouse brain
Feichtmeier et al. Detection of silver nanoparticles in parsley by solid sampling high-resolution–continuum source atomic absorption spectrometry
Karganov et al. Combined use of laser correlation spectroscopy and ICP-AES, ICP-MS determination of macro-and trace elements in human biosubstrates for intoxication risk assessment.
van Elteren et al. Imaging artifacts in continuous scanning 2D LA-ICPMS imaging due to nonsynchronization issues
WO2013140350A3 (fr) Procede et appareil de caracterisation d'echantillons par mesure de la diffusion lumineuse et de la fluorescence.
SG11201802651PA (en) System and method for optically measuring the stability and aggregation of particles
Korinth et al. New methodology to process shifted excitation Raman difference spectroscopy data: a case study of pollen classification
Woess et al. Raman spectroscopy for postmortem interval estimation of human skeletal remains: A scoping review
Konno et al. Endoplasmic Reticulum morphological regulation by RTN4/NOGO modulates neuronal regeneration by curbing luminal transport
Arendt et al. Restricted diffusion of calretinin in cerebellar granule cell dendrites implies Ca2+‐dependent interactions via its EF‐hand 5 domain
Anantha et al. Optical diffraction tomography and Raman spectroscopy reveal distinct cellular phenotypes during white and brown adipocyte differentiation
BRPI0410988A (pt) processo e dispositivo para análise quantitativa de soluções e dispersões por meio de espectroscopia de infravermelho próximo
Colin‐York et al. Quantifying Molecular Dynamics within Complex Cellular Morphologies using LLSM‐FRAP
Cherni et al. Diagnosis of osteoporosis by UV-visible fluorescence of hair in relation to calcium deficiency assessed by the LIBS technique
Parkesh et al. Histological, spectroscopic, and surface analysis of microdamage in bone: toward real-time analysis using fluorescent sensors
BR112018076005A2 (pt) anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
Pchelkina et al. Raman spectroscopic techniques for meat analysis: A review
Emadpoor et al. The relationship between perceived social support with psychological well-being in students.
Chin et al. Effects of E’jiao on skeletal mineralisation, osteocyte and WNT signalling inhibitors in ovariectomised rats
Peng et al. Determination of benzylpenicillin potassium residues in duck meat using surface enhanced raman spectroscopy with Au nanoparticles
Adedipe et al. Rapid measures of user’s adherence to vaginal drug products using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and multivariate discriminant techniques
AR091096A1 (es) Tecnicas de analisis espectral basadas en monitoreo espectral de una matriz
CN105334181A (zh) 辐照食品的快速检测方法
Eggert et al. An automated microphysiological assay for toxicity evaluation